U.S. Healthtech Stock News

AGCO share moves and recent performance snapshot AGCO (AGCO) has drawn investor attention after its recent share performance, with the stock down about 1% over the past day, 7% over the past week, and 20% over the past month. See our latest analysis for AGCO. Those short term share price declines sit against a 90 day share price return of 4.86% and a 1 year total shareholder return of 18.63%. This suggests recent momentum has faded even as longer term holders have still seen gains. If AGCO’s...

The California Public Utilities Commission has issued a proposed decision on California Water Service Group (CWT)’s 2024 General Rate Case, outlining multi year rate increases and mechanisms intended to support fixed cost recovery. See our latest analysis for California Water Service Group. The proposed decision appears to have sharpened investor focus, with a 1 day share price return of 2.24% taking California Water Service Group to $44.24. This comes even though the 1 year total shareholder...

Consolidated Water Co. Ltd. has reported full-year 2025 results, with sales of US$132.07 million versus US$133.97 million a year earlier and net income of US$18.34 million versus US$28.24 million, reflecting softer overall profitability. Despite lower total net income and earnings per share, the company’s earnings per share from continuing operations edged higher, highlighting a relatively stronger performance in its ongoing core businesses. We’ll now examine how the lower full-year net...

Target (NYSE:TGT) faces renewed criticism over its decision to scale back diversity, equity, and inclusion policies while pursuing a reported $6b turnaround plan. Activists and community groups, including many Black consumers, are calling for restoration of earlier DEI commitments and greater transparency from leadership. Public boycotts and pressure on CEO Michael Fiddelke have intensified, raising questions about long term brand perception and customer loyalty. For you as an investor,...

Interest in Visa (V) has picked up as the company leans into stablecoin settlement, AI driven fraud tools and new payment partnerships, prompting investors to reassess the stock after recent share price weakness. See our latest analysis for Visa. Despite a busy period that includes new stablecoin settlement volumes, expanded partnerships with firms like Fiserv and Ingenico, and ongoing regulatory headlines, Visa’s 30 day share price return of 6.19% decline and 1 year total shareholder return...

Sea (NYSE:SE) has been under pressure recently, with the share price showing double digit declines over the month and past 3 months, even as the business continues to generate sizeable revenue and earnings. See our latest analysis for Sea. At a share price of $80.98, Sea’s short term momentum has clearly faded. The 30 day share price return is 25.37% and the year to date share price return is 38.41%, while the 1 year total shareholder return of 36.28% and 5 year total shareholder return of...

Earlier this week, Check Point Software Technologies Ltd. launched its Executive Advisory Board and introduced an integration that streams email security telemetry into CrowdStrike Falcon Next-Gen SIEM, enriching investigations by linking inbox, identity and endpoint activity in one workflow. The new board, led by Nadav Zafrir with co-chair Dave DeWalt, together with deeper CrowdStrike integration, underscores Check Point’s push to deepen AI-led security innovation and broaden its role...

Planet Labs PBC has reported its fourth quarter and full-year 2026 results, with sales rising to US$86.82 million for the quarter and US$307.73 million for the year, alongside a wider net loss of US$152.46 million for the quarter and US$246.86 million for the year. The company also outlined revenue guidance of US$87 million to US$91 million for the first quarter of fiscal 2027 and US$415 million to US$440 million for the full year, while deepening its work with NVIDIA to speed up satellite...

NIO (NYSE:NIO) has filed a large shelf registration that would allow the company to issue additional equity securities in the future. The filing gives NIO flexibility to raise capital in one or multiple offerings over time, subject to market conditions and company needs. This move could affect existing shareholders through potential dilution and may reshape views on NIO's funding approach and balance sheet. NIO's new shelf registration arrives at a time when the stock trades around $5.89,...

This article examines whether Genpact, trading at around US$38.31, is a bargain or a value trap by exploring what the current price actually reflects. The stock has been fairly muted in the short term, with returns of 0.4% over 7 days and 1.5% over 30 days. However, the year-to-date return of a 16.6% decline and a 21.2% decline over the past year will be front of mind for many investors. Recent news coverage has focused on Genpact's position as a global professional services and outsourcing...

Medtronic (NYSE:MDT) has agreed to acquire Scientia Vascular, a maker of guidewires and catheters for complex brain procedures. The deal is intended to strengthen Medtronic’s neurovascular portfolio, with a focus on stroke and other brain vessel interventions. This transaction reflects ongoing investment in specialized products for complex neurovascular care. For investors watching Medtronic’s medical device portfolio, this move adds more depth in neurovascular tools that sit alongside its...

Recent share performance and business snapshot Trade Desk (TTD) has drawn investor attention after a stretch of weak returns, with the stock down about 11% over the past week and 37% over the past 3 months. Over the past year, the share price shows a total return decline of about 58%, alongside annual revenue of US$2.90b and net income of US$443.30m from its global advertising technology platform. See our latest analysis for Trade Desk. At a share price of US$23.51, Trade Desk's recent 7 day...

Earlier this week, Sarepta Therapeutics said it plans to file supplemental new drug applications by the end of April to convert the accelerated approvals of its Duchenne muscular dystrophy exon-skipping drugs AMONDYS 45 and VYONDYS 53 to traditional approvals, using Phase 3 ESSENCE data and real-world evidence that the FDA has agreed to review. The move to seek full approvals for AMONDYS 45 and VYONDYS 53 could be important for the durability of Sarepta’s Duchenne franchise alongside its...

Breckenridge Pharmaceutical has launched Milnacipran HCl Tablets, the first U.S. generic version of AbbVie’s Savella, targeting fibromyalgia patients. Allergan Aesthetics, an AbbVie company, has introduced new global consumer research findings and an evolved AA Signature treatment framework at AMWC 2026. Both developments affect AbbVie’s (NYSE:ABBV) exposure to generic competition and its efforts to refine its aesthetics offering for changing patient preferences. For AbbVie, the Savella...

Alliant Energy filed a $1b at-the-market equity offering program, signaling a sizeable new capital raise. The program allows the company to issue new shares over time into the open market rather than in a single offering. This move comes as Alliant Energy (NasdaqGS:LNT) continues to invest around large data center customers and recent expansion initiatives. Alliant Energy (NasdaqGS:LNT) is coming off a period where the share price is $71.32 and the stock is up 8.7% year to date and 15.8%...

Why a U.S. court decision matters for Burford Capital (BUR) shareholders A U.S. Appeals court has temporarily paused efforts to track Argentine assets in the United States tied to a US$16 billion YPF judgment, directly affecting the Burford Capital (BUR) funded creditor group. This pause keeps the long running dispute in a holding pattern. It matters for investors following how Burford’s legal finance exposure to the Argentina and YPF case interacts with its current US$1.8b market value and...

Event context and recent stock move Rapport Therapeutics (RAPP) shares recently closed at $27.46, with a 3.7% gain over the past day contrasting with negative returns over the week, month, past 3 months, and year to date. See our latest analysis for Rapport Therapeutics. The 1 day share price return of 3.7% comes after weaker recent momentum, with the 30 day share price return at a 5.5% decline and the 90 day share price return at an 11% decline. The 1 year total shareholder return stands at...

Nelnet recently reported a softer quarter, with revenue falling 8.6% year on year and both revenue and EPS coming in below analyst expectations. Despite the weak quarterly performance, the CEO highlighted that Nelnet achieved record earnings in 2025 and emphasized efforts to strengthen the company’s long-term foundation. Next, we’ll explore how the revenue shortfall versus expectations shapes Nelnet’s investment narrative and what it might mean for investors. The latest GPUs need a type of...

Ambarella (AMBA) drew fresh attention after its latest quarter, where revenue and EPS both came in ahead of expectations, highlighting investor interest in the company’s edge AI system-on-chip offerings across cameras, drones and automotive uses. See our latest analysis for Ambarella. The latest earnings beat has been welcomed by the market, with a 3.52% 1 day share price return and 6.56% 7 day share price return. However, the 1 year total shareholder return of 2.23% sits against weaker 3 and...

Coterra Energy (NYSE:CTRA) has entered a definitive all stock merger agreement with Devon Energy Corporation. The transaction is expected to close soon, combining the two businesses into a larger energy producer. The combined company is expected to focus on higher free cash flow and an expanded shareholder return program. For shareholders, this agreement comes after a period of solid share price performance, with NYSE:CTRA at $33.9 and a 27.4% return year to date. Over the past 5 years the...

Nordson stock reaction and recent performance Nordson (NDSN) has been on investors’ radar after a recent pullback, with the share price down about 10% over the past month, while the past 3 months show a positive total return profile. That contrast, combined with a last close of US$267.21 and a one-year total return of 31.8%, is prompting some investors to reassess how the current price lines up with Nordson’s underlying business performance. See our latest analysis for Nordson. That recent...

Why Diversified Energy is Back in Focus Diversified Energy (DEC) is attracting fresh attention after a series of upbeat analyst views and an active share buyback program, a combination that has sharpened investor focus on the stock in recent weeks. See our latest analysis for Diversified Energy. The latest move to a US$16.19 share price, with a 1 month share price return of 23.68% and a 1 year total shareholder return of 26.91%, suggests momentum has picked up even though 3 and 5 year total...

Viasat stock context and recent performance Viasat (VSAT) has drawn fresh attention after recent share price moves. This has prompted investors to reassess how its current valuation lines up with fundamentals, recent returns, and the company’s mix of communication services and defense technologies. Over the past month, the stock has returned 12.8%, with a past 3 months return of 54.2% and a 1 year total return of 442.9%. Year to date, the shares are up 38.5%, while the 3 year total return...

In its latest quarterly report, CRA International posted an 11.6% year-over-year revenue increase, beating analyst forecasts and marking its eighth consecutive annual revenue record, alongside full-year guidance that also exceeded expectations. This combination of stronger-than-anticipated current performance and higher forward revenue guidance highlights how CRA International is currently converting demand for its consulting expertise into sustained top-line momentum. Next, we'll explore...